<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ADDEX THERAPEUTICS 2 RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Mon, 06 Apr 2026 11:34:53 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/addex%5Ftherapeutics%5F2%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>ADDEX THERAPEUTICS 2 RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>Press Release: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Rel...</title><pubDate>Tue, 03 Feb 2026 06:59:52 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/press-release-addex-announces-publication-of-preclinical-data-supporting-potential-of-mglu7-negative-allosteric-modulators-to-transform-anxiety-and-fear-rel-15456681</link><description><![CDATA[<p>Data published in Molecular Psychiatry  Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, February 3, 2026 - https://www.globenewswire.com/Tracker?data=9oqhfe7nilAz9wRZfFH1qtLKm4htn4Luf36xYpupCm1Q9LUOhoaTYXw99Ovpn8Zk5d_KwG4iYO-Xn3AaV2JoaYZRW1Ka91dDM0TiyoTAlII0N7JsM3Zp54jNpNtioYXU  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/press-release-addex-announces-publication-of-preclinical-data-supporting-potential-of-mglu7-negative-allosteric-modulators-to-transform-anxiety-and-fear-rel-15456681</guid></item><item><title>Press Release: Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia</title><pubDate>Wed, 07 Jan 2026 06:59:42 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/press-release-addex-spin-out-neurosterix-has-started-a-phase-1-clinical-study-with-m4-pam-ntx-253-for-schizophrenia-15397708</link><description><![CDATA[<p>Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, January 7, 2026 - https://www.globenewswire.com/Tracker?data=NfweDVg9BAdfQtXZ1wmoyMfW6fBteEhkJep6V2DV5C5nOggy5dbCksQUIazl1pYXlRPAIsYoj_EtIJxPYfpsO1Lqm7bH_qigoMdh0QkCzRc7zhzOxk6hp_QMJ9FVQDB1  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/press-release-addex-spin-out-neurosterix-has-started-a-phase-1-clinical-study-with-m4-pam-ntx-253-for-schizophrenia-15397708</guid></item><item><title>Press Release: Addex Amends its at the Market Offering Agreement With H.C. Wainwright &amp; Co.</title><pubDate>Thu, 11 Dec 2025 06:59:41 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/press-release-addex-amends-its-at-the-market-offering-agreement-with-h-c-wainwright-co-15351106</link><description><![CDATA[<p>Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, December 11, 2025 - <a href="https://www.finanzen.net/aktien/addex_therapeutics-aktie" target="_blank" rel="noopener">Addex Therapeutics</a> (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/press-release-addex-amends-its-at-the-market-offering-agreement-with-h-c-wainwright-co-15351106</guid></item><item><title>Addex Therapeutics: Bilanz zum abgelaufenen Quartal</title><pubDate>Sat, 06 Dec 2025 06:35:07 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/addex-therapeutics-bilanz-zum-abgelaufenen-quartal-15340115</link><description><![CDATA[<p><a href="https://www.finanzen.net/aktien/addex_therapeutics_2-aktie">Addex Therapeutics</a> stellte am 04.12.2025 die jüngste Quartalsbilanz zum am 30.09.2025 abgelaufenen Quartal vor.Addex Therapeutics hat im jüngsten Jahresviertel einen Verlust von 1,50 USD je Aktie erwirtschaftet.  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/addex-therapeutics-bilanz-zum-abgelaufenen-quartal-15340115</guid></item><item><title>Press Release: Addex Therapeutics Reports 2025 -2-</title><pubDate>Thu, 04 Dec 2025 06:59:46 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/press-release-addex-therapeutics-reports-2025-2-15334113</link><description><![CDATA[<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could,"  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/press-release-addex-therapeutics-reports-2025-2-15334113</guid></item><item><title>Press Release: Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update</title><pubDate>Thu, 04 Dec 2025 06:59:42 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/press-release-addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-corporate-update-15334112</link><description><![CDATA[<p>Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, December 4, 2025 - <a href="https://www.finanzen.net/aktien/addex_therapeutics-aktie" target="_blank" rel="noopener">Addex Therapeutics</a> https://www.globenewswire.com/Tracker?data=wNrZQLGoYcayo0lM-4kJ4tjA8 ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/press-release-addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-corporate-update-15334112</guid></item></channel></rss>
